Investigating how brain injuries affect excitability through glutamate release.
Glutamatergic plumes – a novel mechanism of excitability in the brain after TBI.
This study is looking at how brain injuries can make the brain more active in ways that might cause more damage, and it aims to learn about a special process involving a brain chemical called glutamate, which could help find better treatments for people who have had a traumatic brain injury.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas A&m University Health Science Ctr NIH-funded |
| Lab location | 1 site (College Station, United States) |
| Project ID | NIH-11059782 on NIH RePORTER |
What this research studies
This research focuses on understanding the mechanisms that lead to increased brain excitability following traumatic brain injury (TBI). Researchers will study a novel phenomenon called glutamatergic plumes, which are abnormal releases of glutamate that occur after TBI and may contribute to further brain damage. Using advanced techniques like in vivo whole-cell recording and two-photon microscopy, the study will explore how these plumes affect brain function in both male and female mice. The goal is to uncover the underlying causes of excitability changes after TBI, which could lead to better treatment strategies for affected individuals.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have experienced a traumatic brain injury, whether mild or severe.
Not a fit: Patients with conditions unrelated to traumatic brain injury may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches to reduce brain damage and improve recovery outcomes for TBI patients.
How similar studies have performed: While the specific approach of studying glutamatergic plumes is novel, previous research has shown that understanding excitability mechanisms after TBI can lead to significant advancements in treatment.
Where this research is happening
College Station, United States
- Texas A&m University Health Science Ctr — College Station, United States (Active)
Researchers
- Principal investigator: Pokam, Punam Adhik — Texas A&m University Health Science Ctr
- Study coordinator: Pokam, Punam Adhik
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.